P-21 GastroPanel: A blood test to triage dyspeptic patients with atrophic gastritis at risk of developing gastric adenocarcinoma

Gastric adenocarcinoma (GAC) is the 16th most common cancer in UK and has a 5-year survival rate of 20.7%. GastroPanel (Biohit Oyj; Helsinki, Finland) an ELISA kit that measures four plasma biomarkers: Pepsinogen I (PGI), II (PGII), Gastrin 17 (G17) Helicobacter pylori IgG antibodies (Hp IgG), for detection atrophic gastritis (AG). PGI PGI/PGII ratio correlates inversely with severity chronic have been shown to accurately identify patients at risk GAC.This clinical validation study assessed diagnostic accuracy detecting AG among consecutive dyspeptic referred gastroscopy single centre. Two hundred sixty-eight (Females = 151 (56.3%); Median age 57 (range 39-92 years) underwent biopsy histology according updated Sydney system (USS). Blood (plasma) samples analysis were collected index testing[M1]. results interpretation was performed using GastroSoft Oyj, app. [M1]GP test reference (gold standard) Overall agreement between USS classification 90% (95%CI=86.7-93.8%), weighted kappa (κw) 0.828 (95%CI=0.781-0.865). In ROC analysis, moderate/severe corpus (AGC2+) as endpoint, AUC=0.840 (95%CI 0.630-1.000) 0.960 0.907-1.000) ratio, respectively. precise triage test, capable distinguishing functional dyspepsia who can be safely followed up treated conservatively, from those high developing GAC whom mandatory.